Illumina

Committed to the vision to improve human health by unlocking the power of the genome, Illumina has been redefining what is possible in genomics, and empowering visionaries around the globe to make life-changing advances. Illumina develops, manufactures and markets integrated systems for large-scale analysis of genetic variation and biological functions. These systems are used by pharmaceutical companies, biotech companies, academics and clinical organisations around the globe.

When Illumina was founded in San Diego 25 years ago, it was revolutionary just to decode the genome. Since then, genomics has played a crucial role generating insights into infectious disease, cancer, reproductive health, genetic disease, and more—while improving patient outcomes every step of the way. Today, Illumina’s workforce is 10,000 strong, with more than 8,800 patents in 34 locations worldwide.

With light as a core element found in their technology, Illumina’s global brand identity was designed to uniquely express its purpose – to illuminate. The brand also has over 40 trade mark registrations in Singapore, covering products across 8 classes.

“Making genomics accessible is critical in realising its potential to save and improve lives. That’s why we are committed to driving down the cost of sequencing, expanding access to advanced technology, and increasing the diversity of genomics data. And our IP and growth journey in Singapore has helped to fuel this mission.”

- Ms Jennifer Pascua, Vice President, Global IP, Illumina

Illumina’s hub in Singapore is the brand’s only facility worldwide that manufactures the full suite of products ranging from instruments, consumables to reagents. Aside from manufacturing, Singapore hosts Illumina’s first R&D centre in Asia. The centre employs about 1,300 people and houses a multinational team of hardware and software engineers who design and develop some of the company’s newest products.

Illumina’s innovative next-generation sequencing (NGS) platforms deliver exceptional data quality and accuracy, at a massive scale. The portfolio of instruments includes recognisable names such as iSeq™, MiniSeq™, MiSeq™ NextSeq™, and most recently NovaSeq™ X. With rapid advances in technology taking place, Illumina is focused on offering solutions that are not only innovative, but flexible, and scalable, with industry-leading support and service. Their customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.

Find out more at www.illumina.com